155 related articles for article (PubMed ID: 34788990)
1. Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".
Brown JR
Haematologica; 2022 Jun; 107(6):1491-1492. PubMed ID: 34788990
[No Abstract] [Full Text] [Related]
2. Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".
Visentin A; Trentin L
Haematologica; 2022 Jun; 107(6):1489-1490. PubMed ID: 34788988
[No Abstract] [Full Text] [Related]
3. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
4. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib in chronic lymphocytic leukemia.
Martino EA; Bruzzese A; Vigna E; Iaccino E; Mendicino F; Lucia E; Olivito V; Filippelli G; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2023 Apr; 24(5):545-549. PubMed ID: 36943916
[No Abstract] [Full Text] [Related]
6. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Brown JR; Byrd JC; Ghia P; Sharman JP; Hillmen P; Stephens DM; Sun C; Jurczak W; Pagel JM; Ferrajoli A; Patel P; Tao L; Kuptsova-Clarkson N; Moslehi J; Furman RR
Haematologica; 2022 Jun; 107(6):1335-1346. PubMed ID: 34587719
[TBL] [Abstract][Full Text] [Related]
7. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
8. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
9. Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Nierman P
Clin J Oncol Nurs; 2021 Dec; 25(6):687-696. PubMed ID: 34800101
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib for relapsed chronic lymphocytic leukaemia.
Burki TK
Lancet Oncol; 2016 Feb; 17(2):e48. PubMed ID: 26710712
[No Abstract] [Full Text] [Related]
11. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Furman RR; Byrd JC; Owen RG; O'Brien SM; Brown JR; Hillmen P; Stephens DM; Chernyukhin N; Lezhava T; Hamdy AM; Izumi R; Patel P; Baek M; Christian B; Dyer MJS; Streetly MJ; Sun C; Rule S; Wang M; Ghia P; Jurczak W; Pagel JM; Sharman JP
Leukemia; 2021 Nov; 35(11):3201-3211. PubMed ID: 33907299
[TBL] [Abstract][Full Text] [Related]
12. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
13. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
14. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Kumar PS; Wiczer T; Rosen L; Pollauf AJ; Zheng A; Palettas M; Azali L; Bhat SA; Byrd JC; Grever MR; Rogers KA; Woyach JA; Kittai AS
Leukemia; 2023 Jul; 37(7):1554-1557. PubMed ID: 36932166
[No Abstract] [Full Text] [Related]
16. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
17. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
[TBL] [Abstract][Full Text] [Related]
18. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
19. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
